Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells

Cell Cycle

Volumn 8, Issue 12, 2009, Pages 1940-1951

  Kazi, Aslamuzzaman ^a   Lawrence, Harshani ^a   Guida, Wayne C ^a,c   McLaughlin, Mark L ^a,c   Springett, Gregory M ^a,b   Berndt, Norbert ^a   Yip, Richard M L ^a,d   Sebti, Saïd M ^a,b,e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

Apoptosis; Cell proliferation; Cyclin dependent kinase inhibitors; High throughput screening; Nude mice; Proteasome inhibitor

Indexed keywords

ALANINE; ASPARTIC ACID; BORTEZOMIB; CHYMOTRYPSIN; CHYMOTRYPSIN INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GLYCINE; K RAS PROTEIN; NSC 45382; PI 083; PROTEASOME INHIBITOR; PROTEIN SUBUNIT; THREONINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; LUNG CANCER; MOUSE; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE H RAS; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; TUMOR XENOGRAFT;

MUS; MUS MUSCULUS;

EID: 67649394729     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.12.8798     Document Type: Article

References (45)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5:417-421 (Pubitemid 38610244)
2. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23:4776-4789 (Pubitemid 46224082)
3. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin-proteasome system. Nat Rev Cancer 2006; 5:596-612.
4. Hochstrasser M. Ubiquitin, proteasomes and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995; 7:215-223
5. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79:13-21. (Pubitemid 24309509)
6. Wilk S, Orlowski M. Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme. J Neurochem 1980; 35:1172-1182 (Pubitemid 11198291)
7. Hershko A, Heller H, Elias S, Ciechanover A. Components of the ubiquitin-protein ligase system. J Biol Chem 1983; 258:8206-8214
8. Arrigo AP, Tanaka K, Goldberg AL, Welch WJ. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 1988; 331:192-194
9. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65:801-847 (Pubitemid 26255262)
10. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999; 68:1015-1068 (Pubitemid 29449214)
11. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004; 4:349-360 (Pubitemid 38579481)
12. Raff MC. Social controls on cell survivial and cell death. Nature 1992; 356:397-400.
13. Downward J. Targeting ras signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11-22. (Pubitemid 37328883)
14. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications. Eur J Cancer 2004; 40:2217-2229 (Pubitemid 39348871)
15. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle 2005; 4:290-296 (Pubitemid 41365336)
16. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076 (Pubitemid 32691956)
17. Ling Y-h, Liebes L, Zou Y, Perez-Soler R. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. J Biol Chem 2003; 278:33714-33723 (Pubitemid 37553204)
18. Mortenson MM, Schlieman MG, Virudachalam S, Bold RJ. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 nonsmall-cell lung cancer cell line. Cancer Chemother Pharmacol 2004; 54:343-353 (Pubitemid 39304429)
19. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, MCConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003; 2:835-843
20. Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 downregulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 2004; 95:271-275 (Pubitemid 38489096)
21. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents. Cancer Res 1999; 59:2615-2622 (Pubitemid 29269108)
22. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappaB, cell survival, tumor growth and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7:1419-1428 (Pubitemid 32708698)
23. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006; 66:3754-3763
24. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome. J Surg Res 2001; 100:11-17 (Pubitemid 32802698)
25. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003; 10:361-369 (Pubitemid 37296062)
26. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investig 2004; 22:304-311 (Pubitemid 38725184)
27. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783 (Pubitemid 40904528)
28. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762 (Pubitemid 40904525)
29. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8:2505-2511 (Pubitemid 34856332)
30. Scagliotti G. Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol 2006; 58:177-189 (Pubitemid 43796079)
31. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004; 64:5036-5043 (Pubitemid 39006513)
32. Bang SM, Lee JH, Yoon SS, Park S, Min CK, Kim CC, et al. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int J Hematol 2006; 83:309-313 (Pubitemid 43807574)
33. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20S proteasome:TMC-95A complex: A non-covalent proteasome inhibitor. J Mol Biol 2001; 311:543-548 (Pubitemid 32816588)
34. Groll M, Ditzel L, Löwe J, Stock D, Bochtler M, Bartunik HD, Huber R. Structure of the 20S proteasome from yeast at 2.4 A resolution. Nature 1997; 386:463-471 (Pubitemid 27164066)
35. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001; 8:739-758 (Pubitemid 32752454)
36. Groll M, Berkers CR, Ploegh HL, Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 2006; 14:451-456 (Pubitemid 43363478)
37. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2:331-341 (Pubitemid 37328946)
38. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004; 6:171-183 (Pubitemid 39485689)
39. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64:1655-1663 (Pubitemid 38428686)
40. Qian J, Niu J, Li M, Chiao PJ, MS T. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 2005; 65:5045-5053
41. Kip1 in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008; 14:23-35.
42. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8:407-419 (Pubitemid 41579835)
43. Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, et al. Differential cellular and molecular efffects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006; 5:665-675
44. Prescott B. Potential antimalarial agents. Derivatives of 2-chloro-1,4-naphthoquinone. J Med Chem 1969; 12:181-182
45. Kazi A, Wang Z, Kumar N, Falsetti SC, Chan TH, Dou QP. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res 2004; 24:943-954 (Pubitemid 38625043)